NeuroSense Execs Join Roth KOL Webinar on ALS Treatment Future
Event summary
- NeuroSense to participate in Roth-hosted KOL webinar on ALS treatment future July 8, 2026
- Discussion will feature ALS expert Prof. Jeremy Shefner and NeuroSense CEO Alon Ben-Noon
- Webinar to address unmet needs in ALS, trial endpoint design, and PrimeC's development path
- NeuroSense's pivotal Phase 3 PARAGON study in ALS expected to enroll ~300 participants
The big picture
NeuroSense's participation in this high-profile webinar underscores the strategic importance of establishing thought leadership in ALS treatment as it prepares for its pivotal Phase 3 study. The discussion comes at a critical juncture for neurodegenerative disease therapeutics, where demonstrating meaningful clinical outcomes remains the key to commercial success. With ALS representing a $1 billion annual disease burden in the U.S. alone and growing prevalence, successful therapies could capture significant market share.
What we're watching
- Clinical Validation
- Whether PrimeC's multi-target mechanism can demonstrate meaningful disease modification in Phase 3 PARAGON study
- Regulatory Pathway
- The pace at which NeuroSense advances toward potential FDA accelerated approval for PrimeC
- Market Positioning
- How PrimeC differentiates itself in an evolving ALS treatment landscape with growing competition
Related topics